drugset

drugset / Trial / NCT04301726

Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD

NCT04301726 ↗

Phase 1 Terminated 36 enrolled Fundacion Huntington Puerto Rico

RandomizedParallel-groupTriple-blindTreatment

Summary

To determine the efficacy of deutetrabenazine to control symptoms of dysphagia associated with HD.

Timeline

Start: 2022-01-21
Primary completion: 2023-08-18
Completion: 2023-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Deutetrabenazine	Unknown	24 mg	Oral

Indications